Literature DB >> 24330089

Thiazolidinedione use is associated with improved all-cause mortality compared with sulfonylureas among diabetic hemodialysis patients.

Katherine E Lynch1, Connie M Rhee, Steven M Brunelli.   

Abstract

Entities:  

Keywords:  end-stage renal disease; epidemiology; pharmacotherapy; type 2 diabetes

Mesh：

Substances：

Year:  2014        PMID： 24330089      PMCID： PMC4047208          DOI： 10.1111/1753-0407.12115

Source DB:  PubMed          Journal:  J Diabetes        ISSN： 1753-0407            Impact factor:   4.006


× No keyword cloud information.
  9 in total

1.  Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.

Authors:  Nikolaus Marx; Armin Imhof; Johannes Froehlich; Laila Siam; Jochen Ittner; Gerhard Wierse; Arnold Schmidt; Winfried Maerz; Vinzenz Hombach; Wolfgang Koenig
Journal:  Circulation       Date:  2003-04-14       Impact factor: 29.690

2.  Matching methods for causal inference: A review and a look forward.

Authors:  Elizabeth A Stuart
Journal:  Stat Sci       Date:  2010-02-01       Impact factor: 2.901

3.  Emerging analytical techniques for comparative effectiveness research.

Authors:  Steven M Brunelli; Jeremy A Rassen
Journal:  Am J Kidney Dis       Date:  2012-09-26       Impact factor: 8.860

4.  Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.

Authors:  Xiaonan Wang; Zhaoyong Hu; Junping Hu; Jie Du; William E Mitch
Journal:  Endocrinology       Date:  2006-06-15       Impact factor: 4.736

5.  Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy.

Authors:  S Wheeler; K Moore; C W Forsberg; K Riley; J S Floyd; N L Smith; E J Boyko
Journal:  Diabetologia       Date:  2013-06-25       Impact factor: 10.122

6.  Rosiglitazone is associated with mortality in chronic hemodialysis patients.

Authors:  Sylvia P B Ramirez; Justin M Albert; Margaret J Blayney; Francesca Tentori; David A Goodkin; Robert A Wolfe; Eric W Young; George R Bailie; Ronald L Pisoni; Friedrich K Port
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

7.  Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

Authors:  Chih-Sheng Chu; Kun-Tai Lee; Ming-Yi Lee; Ho-Ming Su; Wen-Chol Voon; Sheng-Hsiung Sheu; Wen-Ter Lai
Journal:  Am J Cardiol       Date:  2006-01-09       Impact factor: 2.778

8.  Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes.

Authors:  Steven M Brunelli; Ravi Thadhani; T Alp Ikizler; Harold I Feldman
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

9.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2009-11-10       Impact factor: 2.373
  9 in total
  1 in total

Review 1.  Updates on the management of diabetes in dialysis patients.

Authors:  Connie M Rhee; Angela M Leung; Csaba P Kovesdy; Katherine E Lynch; Gregory A Brent; Kamyar Kalantar-Zadeh
Journal:  Semin Dial       Date:  2014-03       Impact factor: 3.455
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.